Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Disipal 50mg tablets
0409020N0BCAAAM
|
Disipal | Orphenadrine hydrochloride | Central Nervous System | No data available |
|
Disodium folinate 100mg/2ml solution for injection vials
0801000X0AAAAAA
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 200mg/4ml solution for injection vials
0801000X0AAADAD
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 400mg/8ml solution for injection vials
0801000X0AAABAB
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 50mg/1ml solution for injection vials
0801000X0AAAEAE
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 900mg/18ml solution for injection vials
0801000X0AAACAC
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disogram SR 120mg capsules
0206020C0BWAAAU
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disogram SR 180mg capsules
0206020C0BWABAV
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disogram SR 240mg capsules
0206020C0BWACAW
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disogram SR 300mg capsules
0206020C0BWADAE
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disogram SR 60mg capsules
0206020C0BWAEAJ
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disogram SR 90mg capsules
0206020C0BWAFAT
|
Disogram | Diltiazem hydrochloride | Cardiovascular System | No data available |
|
Disophrol modified-release tablets
0310000M0BDAAAD
|
Disophrol | Pseudoephedrine sulfate combinations | Respiratory System | No data available |
|
Disopyramide 100mg/5ml oral liquid
0203020F0AAAVAV
|
Disopyramide | Disopyramide | Cardiovascular System | No data available |
|
Disopyramide 150mg modified-release tablets
0203020G0AAAEAE
|
Disopyramide phosphate | Disopyramide phosphate | Cardiovascular System | No data available |
|
Disopyramide 16mg/5ml oral liquid
0203020F0AAASAS
|
Disopyramide | Disopyramide | Cardiovascular System | No data available |
|
Disopyramide 20mg/5ml oral liquid
0203020F0AAAWAW
|
Disopyramide | Disopyramide | Cardiovascular System | No data available |
|
Disopyramide 250mg modified-release capsules
0203020G0AAABAB
|
Disopyramide phosphate | Disopyramide phosphate | Cardiovascular System | No data available |
|
Disopyramide 25mg/5ml oral liquid
0203020F0AAAXAX
|
Disopyramide | Disopyramide | Cardiovascular System | No data available |
|
Disopyramide 50mg/5ml solution for injection ampoules
0203020G0AAAFAF
|
Disopyramide phosphate | Disopyramide phosphate | Cardiovascular System | No data available |
|
Disposable film rubber sheath
22902409145
|
Disposable film rubber sheath | Urinal Systems | Incontinence Appliances | No data available |
|
Disprin 300mg dispersible tablets
0407010B0BJABAE
|
Disprin | Aspirin | Central Nervous System | No data available |
|
Disprin CV 300mg modified-release tablets
0407010B0BJACCG
|
Disprin | Aspirin | Central Nervous System | No data available |
|
Disprin Direct 300mg orodispersible tablets
0407010B0BJAAAN
|
Disprin | Aspirin | Central Nervous System | No data available |
|
Disprin Extra dispersible tablets
0407010S0BDAAAC
|
Disprin Extra | Aspirin and paracetamol | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.